NASDAQ:KALA KALA BIO (KALA) Stock Price, News & Analysis $5.29 +0.24 (+4.75%) Closing price 07/3/2025 03:44 PM EasternExtended Trading$5.17 -0.12 (-2.34%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About KALA BIO Stock (NASDAQ:KALA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get KALA BIO alerts:Sign Up Key Stats Today's Range$5.05▼$5.3850-Day Range$3.22▼$5.2952-Week Range$2.92▼$11.20Volume54,938 shsAverage Volume45,631 shsMarket Capitalization$34.13 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingBuy Company Overview KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. Read More KALA BIO Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreKALA MarketRank™: KALA BIO scored higher than 68% of companies evaluated by MarketBeat, and ranked 315th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKALA BIO has only been the subject of 2 research reports in the past 90 days.Read more about KALA BIO's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for KALA BIO are expected to grow in the coming year, from ($10.84) to ($6.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KALA BIO is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KALA BIO is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKALA BIO has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about KALA BIO's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.57% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in KALA BIO has recently increased by 0.82%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKALA BIO does not currently pay a dividend.Dividend GrowthKALA BIO does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.35 Percentage of Shares Shorted5.57% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in KALA BIO has recently increased by 0.82%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for KALA BIO this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, KALA BIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $162,876.00 in company stock.Percentage Held by InsidersOnly 8.32% of the stock of KALA BIO is held by insiders.Percentage Held by InstitutionsOnly 24.61% of the stock of KALA BIO is held by institutions.Read more about KALA BIO's insider trading history. Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address KALA Stock News HeadlinesKALA BIO, Inc. (NASDAQ:KALA) CFO Sells $14,560.31 in StockJune 27, 2025 | insidertrades.comKALA BIO, Inc. (KALA) - Yahoo FinanceJuly 1, 2025 | finance.yahoo.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 6 at 2:00 AM | Brownstone Research (Ad)KALA BIO (NASDAQ:KALA) Trading Down 12.2% Following Insider SellingJune 29, 2025 | americanbankingnews.comKALA BIO to Present at Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comKALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | finance.yahoo.comKALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | markets.businessinsider.comKALA BIO to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | finance.yahoo.comSee More Headlines KALA Stock Analysis - Frequently Asked Questions How have KALA shares performed this year? KALA BIO's stock was trading at $6.94 at the beginning of 2025. Since then, KALA stock has decreased by 23.8% and is now trading at $5.29. How were KALA BIO's earnings last quarter? KALA BIO, Inc. (NASDAQ:KALA) posted its earnings results on Friday, March, 28th. The company reported ($1.74) EPS for the quarter, topping the consensus estimate of ($2.28) by $0.54. When did KALA BIO's stock split? KALA BIO shares reverse split on the morning of Friday, October 21st 2022.The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did KALA BIO IPO? KALA BIO (KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. How do I buy shares of KALA BIO? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of KALA BIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL). Company Calendar Last Earnings3/28/2025Today7/06/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KALA CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$15.00 Low Stock Price Target$12.00 Potential Upside/Downside+155.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($8.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.51 million Net MarginsN/A Pretax MarginN/A Return on Equity-369.29% Return on Assets-64.99% Debt Debt-to-Equity Ratio3.19 Current Ratio1.99 Quick Ratio1.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book2.62Miscellaneous Outstanding Shares6,452,000Free Float5,915,000Market Cap$34.13 million OptionableNot Optionable Beta-1.88 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:KALA) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.